Screener
Corcept Therapeutics CORT Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest and other income | 4,631 | 5,017 | 9,517 | 11,219 |
| Income before income taxes | 45,931 | 31,692 | 1,216 | 41,310 |
| Income tax (expense) benefit | (2,944) | 3,457 | 10,010 | 14,386 |
| Net income | 42,987 | 35,149 | 11,226 | 55,696 |
| Net income attributable to common stockholders | 42,141 | 34,611 | 11,017 | 54,918 |
| Basic net income per common share | $0.40 | $0.33 | $0.11 | $0.53 |
| Diluted net income per common share | $0.36 | $0.29 | $0.09 | $0.46 |
| Weighted-average shares outstanding used in computing net income per common share |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's net income?
- Corcept Therapeutics (CORT) reported net income of $42.99M in Q2 2026.
- How has Corcept Therapeutics's net income changed year-over-year?
- Corcept Therapeutics's net income increased by 22.3% year-over-year, from $35.15M to $42.99M.
- What is the long-term trend for Corcept Therapeutics's net income?
- Over 4 years (2021 to 2025), Corcept Therapeutics's net income has grown at a -3.0% compound annual growth rate (CAGR), from $112.51M to $99.65M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Corcept Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude